Dual pathway inhibition demonstrated real-world clinical benefits consistent with randomized trial data among high-risk patients with diabetes mellitus and cardiovascular disease.
Does dual pathway inhibition improve outcomes in patients with diabetes mellitus and cardiovascular disease or peripheral artery disease?
Patients with diabetes mellitus (DM) and cardiovascular disease (CVD) or peripheral artery disease (PAD)
Dual pathway inhibition (DPI)
Real-world data from the XATOA registry supports the benefit of dual pathway inhibition in high-risk patients with diabetes and cardiovascular or peripheral artery disease.
Patients with DM with CVD are at significantly high cardiovascular risk, and those with PAD appear to be undertreated. Real-world outcomes observed in the XATOA registry are consistent with randomized trial data, supporting the benefit of DPI in this high-risk population.
Building similarity graph...
Analyzing shared references across papers
Loading...
Laurence Salle
V. Aboyans
Kai Vogtländer
Vascular Medicine
Inserm
University of Edinburgh
University of Alberta
Building similarity graph...
Analyzing shared references across papers
Loading...
Salle et al. (Mon,) reported a other. Dual pathway inhibition demonstrated real-world clinical benefits consistent with randomized trial data among high-risk patients with diabetes mellitus and cardiovascular disease.
www.synapsesocial.com/papers/69c4cd8dfdc3bde44891a034 — DOI: https://doi.org/10.1177/1358863x261419733
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: